QuickRx Pomalyst (pomalidomide) Copay Assistance

This QuickRx grant provides copay assistance for Pomalyst (pomalidomide) medication to patients with multiple myeloma. It helps commercially insured, Medicare, Medicaid, and uninsured patients reduce out-of-pocket costs to $0 by coordinating manufacturer copay cards, patient assistance programs, and foundation grants. The assistance also includes insurance benefit verification, prior authorization support, and nationwide home delivery.

Eligibility

Eligibility depends on insurance status, requiring commercial insurance for manufacturer copay cards or meeting income-based requirements for foundation grants and patient assistance programs. Patients must also be enrolled in the Pomalyst REMS program and have a valid prescription for an FDA-approved indication like multiple myeloma.